Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Aug 2022
Historique:
pubmed: 2 6 2022
medline: 17 8 2022
entrez: 1 6 2022
Statut: ppublish

Résumé

A patient with follicular lymphoma treated with obinutuzumab and bendamustine experienced prolonged coronavirus disease-2019 (COVID-19). One month after the symptoms transiently improved, the patient experienced exacerbated COVID-19 symptoms. The patient recovered from COVID-19 with remdesivir and dexamethasone and was discharged 77 days after the disease onset. The patient completed a primary series of SARS-CoV-2 vaccinations on day 176, but the anti-spike protein IgG was not detected later. A careful observation to detect any subsequent relapse of COVID-19 symptoms is necessary in immunocompromised patients. Chemotherapy should be based on the disease status and type of lymphoma.

Identifiants

pubmed: 35650124
doi: 10.2169/internalmedicine.9136-21
pmc: PMC9449615
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Rituximab 4F4X42SYQ6
Bendamustine Hydrochloride 981Y8SX18M
obinutuzumab O43472U9X8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2523-2526

Références

Hemasphere. 2021 Feb 10;5(3):e538
pubmed: 33604516
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Eur J Cancer. 2021 Apr;147:154-160
pubmed: 33676266
J Infect Chemother. 2021 Feb;27(2):387-389
pubmed: 33328135
Leuk Lymphoma. 2016;57(3):512-9
pubmed: 26696321
Cochrane Database Syst Rev. 2021 Aug 5;8:CD014962
pubmed: 34350582
Nat Commun. 2020 Dec 14;11(1):6385
pubmed: 33318491
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
J Infect Dis. 2021 May 20;223(9):1522-1527
pubmed: 33556961
Clin Infect Dis. 2021 Apr 26;72(8):1467-1474
pubmed: 33029620
J Infect Dis. 2021 Jan 4;223(1):23-27
pubmed: 33089317
Nat Cancer. 2021 Apr;2(4):392-399
pubmed: 34661163
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
JAMA Netw Open. 2021 Mar 1;4(3):e213071
pubmed: 33760094

Auteurs

Yayoi Ueda (Y)

Department of Internal Medicine, Okayama Rosai Hospital, Japan.

Shoji Asakura (S)

Department of Internal Medicine, Okayama Rosai Hospital, Japan.

Sae Wada (S)

Department of Respiratory Medicine, Okayama Rosai Hospital, Japan.

Takashi Saito (T)

Department of Infectious Diseases, Okayama Medical Center, Japan.

Tomofumi Yano (T)

Department of Internal Medicine, Okayama Rosai Hospital, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH